Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Spectrum Reports First Quarter Profit on Sale, Lower Costs

By Pharmaceutical Processing | May 4, 2011

HENDERSON,
Nev. (AP) — Spectrum Pharmaceuticals
Inc. posted a first-quarter profit today, buoyed by sales of Fusilev and
lower research and development expenses.

The results beat Wall Street estimates, and Spectrum shares
rose 39 cents, or 4.3 percent, to $9.50 in pre-market trading.

The company reported net income of $12.8 million, or 23
cents per share, for the three months ended March 31 compared with a net loss
of $39 million, or 80 cents per share, a year ago. Revenue surged to $43.6
million from $11.1 million.

Analysts expected the company to report earnings of 15 cents
per share on $28.6 million in revenue, according to FactSet.

The company reported $35 million in sales from its drug
Fusilev, up from $600,000 a year prior. The drug is used to treat the side
effects of the chemotherapy drug methotrexate. It is approved for use in
patients who are being treated for osteosarcoma, a type of bone cancer, and to
reduce the toxicity of methotrexate.

Sales of the lymphoma drug Zevalin remained flat at $6
million and the company reported $3 million in licensing payments.

Operating expenses fell 49 percent to $26.1 million.

“With modest needs for running our day to day operations,
we believe Spectrum is firmly on the road to continued success,” said
President and CEO Dr. Rajesh C. Shrotriya, in a statement.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE